Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Gilder Gagnon Howe & Co. LLC

Gilder Gagnon Howe & Co. LLC raised its stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 6.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 931,894 shares of the medical device company’s stock after purchasing an additional 58,920 shares during the period. Gilder Gagnon Howe & Co. LLC owned about 1.42% of Tandem Diabetes Care worth $33,567,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Hood River Capital Management LLC acquired a new stake in Tandem Diabetes Care in the fourth quarter valued at approximately $46,035,000. Baillie Gifford & Co. raised its holdings in shares of Tandem Diabetes Care by 235.7% in the 4th quarter. Baillie Gifford & Co. now owns 746,109 shares of the medical device company’s stock valued at $26,875,000 after purchasing an additional 523,843 shares in the last quarter. GW&K Investment Management LLC lifted its position in shares of Tandem Diabetes Care by 18.0% during the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company’s stock worth $76,488,000 after purchasing an additional 323,674 shares during the last quarter. Stephens Investment Management Group LLC grew its stake in shares of Tandem Diabetes Care by 22.1% during the fourth quarter. Stephens Investment Management Group LLC now owns 1,555,809 shares of the medical device company’s stock worth $56,040,000 after purchasing an additional 281,327 shares in the last quarter. Finally, Barclays PLC increased its holdings in Tandem Diabetes Care by 106.4% in the fourth quarter. Barclays PLC now owns 476,974 shares of the medical device company’s stock valued at $17,180,000 after buying an additional 245,909 shares during the last quarter.

Tandem Diabetes Care Stock Performance

Shares of TNDM opened at $18.06 on Friday. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The stock has a market capitalization of $1.20 billion, a P/E ratio of -9.36 and a beta of 1.52. The company has a debt-to-equity ratio of 1.29, a quick ratio of 2.32 and a current ratio of 2.90. The company’s fifty day moving average is $20.17 and its two-hundred day moving average is $29.29.

Insider Transactions at Tandem Diabetes Care

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business’s stock in a transaction on Friday, March 7th. The stock was purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares of the company’s stock, valued at $190,948.56. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Sanford C. Bernstein cut Tandem Diabetes Care from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $35.00 to $25.00 in a research report on Friday, February 28th. The Goldman Sachs Group dropped their price target on shares of Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Mizuho initiated coverage on shares of Tandem Diabetes Care in a research report on Thursday, April 10th. They set a “neutral” rating and a $20.00 price objective for the company. Royal Bank of Canada dropped their target price on shares of Tandem Diabetes Care from $65.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Eight equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.81.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.